The company said it expects GAAP shareholders' net income for Q1 2025 of $9.61 per diluted share, including net unfavorable items of about $2.36 per diluted share. It said adjusted shareholders' net income, excluding those items, was $11.97 per diluted share.

1. 01

   The company said it expects GAAP shareholders' net income for Q1 2025 of $9.61 per diluted share, including net unfavorable items of about $2.36 per diluted share. It said adjusted shareholders' net income, excluding those items, was $11.97 per diluted share.

2. 02

   Elevance Health said medical cost trends for Q1 developed in line with its expectations, including in its Medicare Advantage business. It said that while Medicare Advantage cost trends remain elevated, its Q1 experience was consistent with its expectations and pricing.

3. 03

   Elevance Health said it continues to expect full-year 2025 Medicare Advantage membership of 2,200 to 2,250 thousand members, in line with the outlook it provided in its earnings release on January 23, 2025 for Q4 2024.

4. 04

   The company said that, based on Q1 results and its outlook, it intends to reaffirm its full-year 2025 adjusted shareholders' net income guidance of $34.15 to $34.85 per diluted share. It said it will provide additional details on Q1 results and its full-year outlook when it reports results on April 22, 2025.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.